sorry, we can't preview this file

...but you can still download Supplementary Table 1.docx
Supplementary Table 1.docx (14.34 kB)

Supplementary Table 1 - Engineered mesoporous silica reduces long-term blood glucose and HbA1c, and improve metabolic parameters in prediabetics

Download (14.34 kB)
posted on 02.12.2021, 14:23 by Jeanha Baek, Ghislaine Robert-Nicoud, Carmen Herrera Hidalgo, Melissa L. Borg, Muhammad N. Iqbal, Roger Berlin, Maria Lindgren, Erik Waara, Anna Uddén, Kirsi Pietiläinen, Tore Bengtsson

Supplementary Table 1. Baseline characteristics of all participants in the trial.

Data are presented as Mean + SD.


T Bengtsson is supported by the Vetenskapsradet Medicin (VR-M) from the Swedish Research Council. T Bengtsson owns stock in the following pharmaceutical companies: Sigrid Therapeutics AB, Atrogi AB and Glucox Biotechnology AB. The following authors are or were employed by Sigrid Therapeutics AB: J Baek, G Robert-Nicoud, C. Herrera Hidalgo, ML Borg, MN Iqbal, M Lindgren, ER Waara, A Uddén. T Bengtsson is one of the inventors of the patent family WO2014072363A1. T Bengtsson and MN Iqbal are inventors of the patent family WO2019166656A1.